Application of nomograms in the prediction of overall survival and cancer‑specific survival in patients with T1 high‑grade bladder cancer

Tang,Fucai; He,Zhaohui; Lu,Zechao; Wu,Weijia; Chen,Yiwen; Wei,Genggeng; Liu,Yangzhou

doi:10.3892/etm.2019.7979

Application of nomograms in the prediction of overall survival and cancer‑specific survival in patients with T1 high‑grade bladder cancer

Authors:
- Fucai Tang
- Zhaohui He
- Zechao Lu
- Weijia Wu
- Yiwen Chen
- Genggeng Wei
- Yangzhou Liu
View Affiliations

Affiliations: Department of Urology, The Eighth Affiliated Hospital, Sun Yat‑Sen University, Shenzhen, Guangdong 518033, P.R. China, The First Clinical College of Guangzhou Medical University, Guangzhou, Guangdong 510230, P.R. China, Deparement of Urology, Longgang District Central Hospital, Shenzhen, Guangdong 518100, P.R. China, Department of Urology, Hongkong University‑Shenzhen Hospital, Shenzhen, Guangdong 518053, P.R. China, Department of Urology, Minimally Invasive Surgery Center, Guangdong Provincial Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510230, P.R. China
Published online on: September 6, 2019 https://doi.org/10.3892/etm.2019.7979
Pages: 3405-3414
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To predict survival outcomes for individual patients with clinical T1 high‑grade (T1HG) bladder cancer (BC), data from the Surveillance Epidemiology and End Results (SEER) database were analyzed in the present study. The data of 6,980 cases of T1HG BC between 2004 and 2014 were obtained from the SEER database. Uni‑ and multivariate Cox analyses were performed to identify significant prognostic factors. Subsequently, prognostic nomograms for predicting 3‑ and 5‑year overall survival (OS) and cancer‑specific survival (CSS) rates were constructed based on the SEER database. Clinical information from the SEER database was divided into internal and external groups and used to validate the nomograms. In addition, calibration plot diagrams and concordance indices (C‑indices) were used to verify the predictive performance of the nomogram. A total of 6,980 patients were randomly allocated to the training cohort (n=4,886) or the validation cohort (n=2094). Univariate and multivariate Cox analyses indicated that age, ethnicity, tumor size, marital status, radiation and surgical status were independent prognostic factors. These characteristics were used to establish nomograms. The C‑indices for OS and CSS rate predictions for the training cohort were 0.707 (95% CI, 0.693‑0.721) and 0.700 (95% CI, 0.679‑0.721), respectively. Internal and external calibration plot diagrams exhibited an excellent consistency between actual survival rates and nomogram predictions, particularly for 3‑ and 5‑year OS and CSS. The significant prognostic factors in patients with T1HG BC were age, ethnicity, marital status, tumor size, status of surgery and use of radiation. In the present study, a nomogram was developed that may serve as an effective and convenient evaluation tool to help surgeons perform individualized survival evaluations and mortality risk determination for patients with T1HG BC.

View Figures

View References

1	Chavan S, Bray F, Lortet-Tieulent J, Goodman M and Jemal A: International variations in bladder cancer incidence and mortality. Eur Urol. 66:59–73. 2014. View Article : Google Scholar : PubMed/NCBI
2	Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S and Stenzl A: Economic aspects of bladder cancer: What are the benefits and costs? World J Urol. 27:295–300. 2009. View Article : Google Scholar : PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
4	Colombo R, Hurle R, Moschini M, Freschi M, Colombo P, Colecchia M, Ferrari L, Lucianò R, Conti G, Magnani T, et al: Feasibility and clinical roles of different substaging systems at first and second transurethral resection in patients with T1 high-grade bladder cancer. Eur Urol Focus. 4:87–93. 2018. View Article : Google Scholar : PubMed/NCBI
5	Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of bladder: Update 2013. Eur Urol. 64:639–653. 2013. View Article : Google Scholar : PubMed/NCBI
6	Proctor I, Stoeber K and Williams GH: Biomarkers in bladder cancer. Histopathology. 57:1–13. 2010. View Article : Google Scholar : PubMed/NCBI
7	Goodison S, Rosser CJ and Urquidi V: Bladder cancer detection and monitoring: Assessment of urine- and blood-based marker tests. Mol Diagn Ther. 17:71–84. 2013. View Article : Google Scholar : PubMed/NCBI
8	van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol. 56:430–442. 2009. View Article : Google Scholar : PubMed/NCBI
9	Fransen van de Putte EE, Behrendt MA, Pigot GL, van der Kwast TH and van Rhijn BW: Prognostic significance of substage and WHO classification systems in T1 urothelial carcinoma of the bladder. Curr Opin Urol. 25:427–435. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kitamura H and kakehi Y: Treatment and management of high-grade T1 bladder cancer: What should we do after second TUR? Jpn J Clin Oncol. 45:315–322. 2015. View Article : Google Scholar : PubMed/NCBI
11	Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016. Eur Urol. 71:447–461. 2017. View Article : Google Scholar : PubMed/NCBI
12	Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, et al: Predicting non-muscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model. J Urol. 182:2195–2203. 2009. View Article : Google Scholar : PubMed/NCBI
13	Song K, Shi X, Wang H, Zou F, Lu F, Ma X, Xia X and Jiang J: Can a nomogram help to predict the overall and cancer-specific survival of patients with chondrosarcoma? Clin Orthop Relat Res. 476:987–996. 2018. View Article : Google Scholar : PubMed/NCBI
14	Fang C, Wang W, Feng X, Sun J, Zhang Y, Zeng Y, Wang J, Chen H, Cai M, Lin J, et al: Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms. Br J Cancer. 117:1544–1550. 2017. View Article : Google Scholar : PubMed/NCBI
15	Dong F, Shen Y, Gao F, Shi X, Xu T, Wang X, Zhang X, Zhong S, Zhang M, Chen S and Shen Z: Nomograms to predict individual prognosis of patients with primary small cell carcinoma of the bladder. J Cancer. 9:1152–1164. 2018. View Article : Google Scholar : PubMed/NCBI
16	Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC cancer staging manual. 8th. New York: Springer; 2017, View Article : Google Scholar
17	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004. View Article : Google Scholar : PubMed/NCBI
18	Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Hussein Al Awamlh B, Trinh QD, Sun M, et al: Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. Urol Oncol. 32:433–440. 2014. View Article : Google Scholar : PubMed/NCBI
19	Xylinas E, Kluth LA, Lotan Y, Daneshmand S, Rieken M, Karakiewicz PI and Shariat SF: Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol. 32:230–242. 2014. View Article : Google Scholar : PubMed/NCBI
20	Valentini V, van Stiphout RG, Lammering G, Gambacorta MA, Barba MC, Bebenek M, Bonnetain F, Bosset JF, Bujko K, Cionini L, et al: Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 29:3163–3172. 2011. View Article : Google Scholar : PubMed/NCBI
21	Balachandran VP, Gonen M, Smith JJ and DeMatteo RP: Nomograms in oncology: More than meets the eye. Lancet Oncol. 16:e173–e80. 2015. View Article : Google Scholar : PubMed/NCBI
22	Kim MS, Lee SY, Lee TR, Cho WH, Song WS, Koh JS, Lee JA, Yoo JY and Jeon DG: Prognostic nomogram for predicting the 5-year probability of developing metastasis after neo-adjuvant chemotherapy and definitive surgery for AJCC stage II extremity osteosarcoma. Ann Oncol. 20:955–960. 2009. View Article : Google Scholar : PubMed/NCBI
23	Al-Daghmin A, English S, Kauffman EC, Din R, Khan A, Syed JR, Sztorc J, Mehedint D, Sharif M, Shi Y, et al: External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder. BJU Int. 114:253–260. 2014. View Article : Google Scholar : PubMed/NCBI
24	Brooks M, Godoy G, Sun M, Shariat SF, Amiel GE and Lerner SP: External validation of bladder cancer predictive nomograms for recurrence, cancer-free survival and overall survival following radical cystectomy. J Urol. 195:283–289. 2016. View Article : Google Scholar : PubMed/NCBI
25	Ishioka J, Saito K, Sakura M, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Kawakami S and Kihara K: Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. Br J Cancer. 107:1031–1036. 2012. View Article : Google Scholar : PubMed/NCBI
26	Fujii N, Hoshii Y, Hirata H, Mori J, Shimizu K, Kobayashi K, Kawai Y, Inoue R, Yamamoto Y, Matsumoto H, et al: Impact of divergent differentiation in urothelial carcinoma on oncological outcome in patients with T1 high-grade bladder cancer. Jpn J Clin Oncol. 47:560–567. 2017. View Article : Google Scholar : PubMed/NCBI
27	Merrill RM and Johnson E: Benefits of marriage on relative and conditional relative cancer survival differ between males and females in the USA. J Cancer Surviv. 11:578–589. 2017. View Article : Google Scholar : PubMed/NCBI
28	Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR and Saigal CS; Urologic Diseases in America Project, : Recurrence of high-risk bladder cancer: A population-based analysis. Cancer. 119:3219–3227. 2013. View Article : Google Scholar : PubMed/NCBI
29	Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, et al: Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. Cancer Epidemiol. 37:219–225. 2013. View Article : Google Scholar : PubMed/NCBI
30	Brookfield KF, Cheung MC, Gomez C, Yang R, Nieder AM, Lee DJ and Koniaris LG: Survival disparities among African American women with invasive bladder cancer in Florida. Cancer. 115:4196–4209. 2009. View Article : Google Scholar : PubMed/NCBI
31	Mallin K, David KA, Carroll PR, Milowsky MI and Nanus DM: Transitional cell carcinoma of the bladder: Racial and gender disparities in survival (1993 to 2002), stage and grade (1993 to 2007). J Urol. 185:1631–1636. 2011. View Article : Google Scholar : PubMed/NCBI
32	Ward EM, Fedewa SA, Cokkinides V and Virgo K: The association of insurance and stage at diagnosis among patients aged 55 to 74 years in the national cancer database. Cancer J. 16:614–621. 2010. View Article : Google Scholar : PubMed/NCBI
33	Weiss C, Ott OJ, Wittlinger M, Krause SF, Fietkau R, Sauer R and Rödel C: Treatment options for high-risk T1 bladder cancer: Status quo and future perspectives of radiochemotherapy. Strahlenther Onkol. 184:443–449. 2008. View Article : Google Scholar : PubMed/NCBI
34	Vartolomei MD, Ferro M, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, Guazzoni G, Busetto GM, De Berardinis E, Damiano R, et al: Validation of neutrophil-to-lymphocyte ratio in a multi-institutional cohort of patients with T1G3 non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 16:445–452. 2018. View Article : Google Scholar : PubMed/NCBI
35	Canter D, Egleston B, Wong YN, Smaldone MC, Simhan J, Greenberg RE, Uzzo RG and Kutikov A: Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: A SEER database analysis. Urol Oncol. 31:866–870. 2013. View Article : Google Scholar : PubMed/NCBI
36	Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, et al: Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort. Eur Urol. 66:156–163. 2014. View Article : Google Scholar : PubMed/NCBI
37	Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, Raj G, Bochner BH, Dalbagni G, Herr HW and Donat SM: Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 55:164–174. 2009. View Article : Google Scholar : PubMed/NCBI
38	Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, et al: The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int. 118:44–52. 2016. View Article : Google Scholar : PubMed/NCBI
39	Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, et al: Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: Results from an international cohort. Eur Urol. 57:300–309. 2010. View Article : Google Scholar : PubMed/NCBI
40	Soria F, Marra G, D'Andrea D, Gontero P and Shariat SF: The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer. Transl Androl Urol. 8:46–53. 2019. View Article : Google Scholar : PubMed/NCBI